Perphenazine Tablet, Film Coated
NDC Package 0591-4101-01
Package Information
Perphenazine tablets is a medication used to treat certain mental/mood disorders (e.g., schizophrenia, manic phase of bipolar disorder, schizoaffective disorder). This formulation utilizes a tablet, film coated delivery system. Marketed by Actavis Pharma, Inc., this product is identified by NDC 0591-4101 and is authorized under FDA application ANDA207582.
Identification & Billing
- RxCUI: 198075 - perphenazine 16 MG Oral Tablet
- RxCUI: 198076 - perphenazine 2 MG Oral Tablet
- RxCUI: 198077 - perphenazine 4 MG Oral Tablet
- RxCUI: 198078 - perphenazine 8 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0591 - Actavis Pharma, Inc.
- 0591-4101 - Perphenazine
- 0591-4101-01 - 100 TABLET, FILM COATED in 1 BOTTLE
- 0591-4101 - Perphenazine
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (0591-4101). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0591-4101-01 identifies a specific commercial package of 100 tablet, film coated in 1 bottle of Perphenazine, a human prescription drug labeled by Actavis Pharma, Inc.. This tablet, film coated is formulated for oral use and contains perphenazine as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Actavis Pharma, Inc. on May 30, 2017. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used to treat certain mental/mood disorders (e.g., schizophrenia, manic phase of bipolar disorder, schizoaffective disorder). This medicine helps you to think more clearly, feel less nervous, and take part in everyday life. It can reduce aggressive behavior and the desire to hurt yourself/others. It may also help to decrease hallucinations (e.g., hearing/seeing things that are not there). Perphenazine is a psychiatric medication (antipsychotic-type) that works by helping to restore the balance of certain natural substances (e.g., dopamine) in the brain.
How is this Actavis Pharma, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00591410101. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.